Myles Brown
Affiliations: | Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States |
Google:
"Myles Brown"Parents
Sign in to add mentor| George Khoury | research assistant | 1974-1981 | (Microtree) | |
| David M. Livingston | post-doc | 1982-1986 | (Neurotree) | |
| (BWH Research Resident) | ||||
| Phillip Allen Sharp | post-doc | 1987-1990 | ||
Children
Sign in to add trainee| David Chi | grad student | Dana-Farber Cancer Institute, Harvard Medical School | |
| Jason Carroll | post-doc | Dana-Farber Cancer Institute, Harvard Medical School | |
| Laura Cato | post-doc | ||
| James DiRenzo | post-doc | Dana-Farber Cancer Institute, Harvard Medical School | |
| Anna Groner | post-doc | ||
| Rinath Jeselsohn | post-doc | Dana-Farber Cancer Institute, Harvard Medical School | |
| David Labbé | post-doc | McGill | |
| Yongfeng Shang | post-doc | ||
| Wenlin Shao | post-doc | ||
| Mathieu Lupien | post-doc | 2005-2008 | Dana-Farber Cancer Institute, Harvard Medical School |
| Hansen Housheng He | post-doc | 2008-2013 | Dana-Farber Cancer Institute (Chemistry Tree) |
Collaborators
Sign in to add collaborator| Xiaole Shirley Liu | collaborator | ||
| Eliezer M. Van Allen | collaborator | (Neurotree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Neeb A, Figueiredo I, Bogdan D, et al. (2024) Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. Molecular Cancer Therapeutics |
| Venkadakrishnan VB, Presser AG, Singh R, et al. (2024) Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Research Square |
| Poluben L, Nouri M, Liang J, et al. (2024) Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer. Biorxiv : the Preprint Server For Biology |
| Jovanović B, Temko D, Stevens LE, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Reports. 42: 113564 |
| Wu G, Yoshida N, Liu J, et al. (2023) TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence. Science Translational Medicine. 15: eadi7244 |
| Qiu X, Brown LG, Conner JL, et al. (2022) Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. Jci Insight. 7 |
| Qiu X, Boufaied N, Hallal T, et al. (2022) MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications. 13: 2559 |
| Kuznik NC, Solozobova V, Lee II, et al. (2022) A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway. Iscience. 25: 104175 |
| DeCaprio JA, Brown M. (2022) David M. Livingston 1941-2021. Nature Cancer. 2: 1276-1277 |
| Liao Y, Chen CH, Xiao T, et al. (2022) Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America. 119 |